U.S. Biosimilar Guidances: Bridging, Extrapolation And Immunogenicity
This article was originally published in PharmAsia News
New draft Q&A and three final guidances from the U.S. FDA offer pros and cons for sponsors of biosimilar applications in this major market and provide substantial additional details on the agency’s regulatory approach to such products.
You may also be interested in...
CooperSurgical is hit with second letter for misleading promotion of its copper-containing intrauterine contraceptive. Video lacked any safety information, agency says in request for corrective communication.
Pfizer and Moderna execs note they have sufficient resources with their partners to meet their vaccine production commitments. J&J, which has a manufacturing arrangement with Sanofi, is ready to ship four million doses of its vaccine upon receiving authorization from FDA.
Pfizer and Genentech execs describe steps they’ve taken to increase diversity in clinical trials from moving trial sites into new neighborhoods to modifying protocols and holding others accountable for diversity.